CORT: Corcept Therapeutics Incorporated Stock

by  •  • Comments Off on CORT: Corcept Therapeutics Incorporated Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5,859.03
Enterprise Value ($M) 5,721.74
Book Value ($M) 638.84
Book Value / Share 6.10
Price / Book 9.17
NCAV ($M) 321.56
NCAV / Share 3.07
Price / NCAV 18.22

Profitability (mra)
Return on Invested Capital (ROIC) 0.22
Return on Assets (ROA) 0.24
Return on Equity (ROE) 0.31

Liquidity (mrq)
Quick Ratio 3.64
Current Ratio 3.70

Balance Sheet (mrq) ($M)
Current Assets 466.98
Assets 784.26
Liabilities 145.42
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Potentially Dilutive Securities Stock Options Outstanding n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
03-27 13G/A Ingalls & Snyder Llc 8.00 16.53
02-14 13G/A Baker G Leonard Jr 5.30 0.50
02-13 13G/A Vanguard Group Inc 9.25 -7.81
02-13 13G/A Renaissance Technologies Llc 6.52 -7.72
02-12 13G/A Belanoff Joseph K 6.10 8.22
01-22 13G/A BlackRock, Inc. 15.90 0.37

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-10-30 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri
2024-07-29 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri
2024-05-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _______________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly peri
2024-02-15 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-22 134,556 542,968 24.78
2024-11-21 124,401 493,673 25.20
2024-11-20 166,852 822,512 20.29
2024-11-19 101,117 428,539 23.60

(click for more detail)

Similar Companies
CNTX – Context Therapeutics Inc. COCP – Cocrystal Pharma, Inc.
COEP – Coeptis Therapeutics Holdings, Inc. COYA – Coya Therapeutics, Inc.
CPRX – Catalyst Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Corcept Therapeutics